Cyramza for Non-Small Cell Lung Cancer - Details


( Last Updated : May 20, 2016)
Generic Name:
Ramucirumab
Project Status:
Cancelled
Manufacturer:
Eli Lilly Canada Inc.
Brand Name:
Cyramza
Project Line:
Reimbursement Review
Project Number:
PC0078-000

Details


Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer
Funding Request:
For the treatment of patients with advanced or metastatic non-small cell lung cancer who progressed on or after platinum-based chemotherapy in combination with docetaxel
Review Status:
Cancelled
Pre Noc Submission:
Yes
Sponsor:
Eli Lilly Canada Inc.
Clarification:
The submitter notified pCODR that they will not be filing the submission.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.